pharma · Myelofibrosis · Acute Myeloid Leukemia
Karyopharm Therapeutics
Karyopharm Therapeutics Inc
Karyopharm Therapeutics is a pharma organization headquartered in Newton, USA. Primary therapeutic focus areas include Myelofibrosis, Acute Myeloid Leukemia, Multiple Myeloma, Thymoma, Myeloma Multiple. NovaPharmaNews li
85 Wells Avenue, Newton, MA 02459, US HQ
313 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- 85 Wells Avenue, Newton, MA 02459, US
- Employees
- 313
- Programs
- 82
- Drugs
- 53
- Patents
- 38
XPORT-MF-044
Phase 2 · small molecule · moderate thrombocytopenia, JAK inhibitor-naïve myelofibrosis
XPORT-MF-044 for moderate thrombocytopenia, JAK inhibitor-naïve myelofibrosis is a Phase 2 program (small_molecule) at Karyopharm Therapeutics Inc with 1 ClinicalTrials.gov record(s).
Internal code XPORT-MF-044
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Karyopharm Therapeutics Inc
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- moderate thrombocytopenia, JAK inhibitor-naïve myelofibrosis
- Status
- active
- Trials
- 1